Vilgrain I, Gonzalez A M, Baird A
Department of Molecular and Cellular Growth Biology, Whittier Institute for Diabetes and Endocrinology, La Jolla, CA 92037.
FEBS Lett. 1993 Oct 4;331(3):228-32. doi: 10.1016/0014-5793(93)80342-r.
The subcellular fractions containing protein kinases capable of phosphorylating basic fibroblast growth factor (FGF-2) are unknown, but having previously characterized one that is associated with the plasma membrane [1991, Mol. Endocrinol. 5, 1003-1012] we evaluated the catalytic properties of another in the nucleus. The reaction is time (linear up to 15 min), enzyme (2,000-25,000 nuclei/ml), and substrate (Km 0.18 microM) dependent, and the targets serine. DNase pretreatment of nuclei decreases the incorporation of phosphate into FGF-2 by 50% and the reaction. It is also inhibited by heparin (EC50 1 microgram/ml) and spermidine (EC50 3 microM). Calcium and cAMP have no effect. We conclude that the kinase is distinct from PKA, and PKC, and suggest that changes in glycosaminoglycan and polyamine concentrations during the cell cycle may modulate FGF-2 phosphorylation in the nucleus, or as it is translocated to the nucleus.
能够磷酸化碱性成纤维细胞生长因子(FGF - 2)的亚细胞组分尚不清楚,但我们之前已鉴定出一种与质膜相关的组分[1991年,《分子内分泌学》5卷,1003 - 1012页],在此基础上,我们评估了细胞核中另一种组分的催化特性。该反应依赖于时间(长达15分钟呈线性)、酶(2000 - 25000个细胞核/毫升)和底物(Km为0.18微摩尔),且磷酸化靶点为丝氨酸。用脱氧核糖核酸酶预处理细胞核会使FGF - 2的磷酸掺入量减少50%,并抑制该反应。它也受到肝素(半数有效浓度为1微克/毫升)和亚精胺(半数有效浓度为3微摩尔)的抑制。钙和环磷酸腺苷无影响。我们得出结论,该激酶不同于蛋白激酶A和蛋白激酶C,并表明在细胞周期中糖胺聚糖和多胺浓度的变化可能会调节细胞核中FGF - 2的磷酸化,或者在其转运至细胞核的过程中发挥调节作用。